Ceralasertib (AZD6738) Trial
Phase 2
89
about 9.2 years
18+
3 sites in CA, IL
What this study is about
This trial is testing ceralasertib, a drug that blocks enzymes needed for cell growth, alone or in combination with olaparib or durvalumab to treat various types of solid tumors. The goal is to see if this treatment can stop the growth of tumor cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ceralasertib
- 2.Take Durvalumab
- 3.Take Olaparib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
durvalumab, olaparib
infusion, oral
Primary: Composite Prostate Cancer Patient Response Rate (prostate cancer only), Objective response rate (ORR) (ARID1A cohort), Objective response rate (ORR) for endometrial cohort, Objective response rate (ORR) for other solid tumors
Secondary: Median Overall Survival (Endometrial cohort only), Median duration of response (DOR) by disease group, Median duration of response (DOR) by treatment regimen, Median progression-free survival (PFS) at 12 months by disease group, Median progression-free survival (PFS) at 12 months by treatment regimen, Median progression-free survival (PFS) at 6 months by disease group, Median progression-free survival (PFS) at 6 months by treatment regimen, Progression-free survival (PFS) rate over time
Oncology